Clinical Trial Update: Chiauranib Plus PD-1 Inhibitor, Albumin-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma [Phase 3]

View source ↗

Summary

This is a Phase 3 clinical trial evaluating chiauranib in combination with a PD-1 inhibitor, albumin-bound paclitaxel, and gemcitabine for metastatic pancreatic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Ductal Adenocarcinoma

Drugs mentioned

• Albumin-bound paclitaxel (nab-paclitaxel)
• Chiauranib (Chiauranib)
• Gemcitabine (Gemcitabine)
• PD-1 inhibitor

Snippet

Sponsor: Chipscreen Biosciences, Ltd. | Conditions: Metastatic Pancreatic Ductal Adenocarcinoma | Phase 3 | Status: NOT_YET_RECRUITING